Inaktiver Wert

Andere Sprachen Oncolytics Biotech Inc. Nasdaq

Aktien

CA6823101077

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	13.05.
Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer	10.05.
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million	09.05.
Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09	09.05.
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights	09.05.
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer	09.05.
Oncolytics Biotech Brief: Says Received Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer	09.05.
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer	09.05.
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference	08.05.
Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	01.05.
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	30.04.
Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	26.04.
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	25.04.
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K	12.04.
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	12.04.
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	11.04.
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	11.04.
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	11.04.
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	11.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Oncolytics Biotech Inc. Nasdaq

Aktien

CA6823101077

Andere Sprachen

Filter